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CASE REPORT
SEROLOGICAL MONITORING OF A Toxoplasma INFECTION AFTER HEMATOPOIETIC 
STEM CELL TRANSPLANTATION
Cláudio L. ROSSI(1), Fernanda S. NASCIMENTO(1), Sílvia de BARROS-MAZON(1), Daniela F. DIAS(2), Antonio C. VIGORITO(2) & Cármino A. de SOUZA(2)
SUMMARY
We report a primary response to Toxoplasma gondii following a hematopoietic stem cell transplantation in a patient with multiple 
myeloma. The primary response to T. gondii was supported by IgM, IgG and IgA seroconversion. The patient was promptly treated 
and there were no complications related to toxoplasmosis in the subsequent months.
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INTRODUCTION
Toxoplasmosis, a worldwide infection caused by the intracellular 
parasite Toxoplasma gondii, is generally asymptomatic or is associated 
with mild, non-specific clinical manifestations in immunocompetent 
subjects. The parasite can, however, cause serious illness in congenitally 
infected infants2 and in immunocompromised patients1,4. We report a 
primary response to T. gondii following a non-myeloablative allogeneic 
hematopoietic stem cell transplantation in a patient with multiple 
myeloma.
CASE REPORT
A 53-year-old Brazilian man was diagnosed in December 1998 as 
having multiple myeloma (stage IIIA according to Durie and Salmon’s 
classification). The patient achieved partial remission after VAD 
chemotherapy. In April 2000, he underwent an autologous hematopoietic 
stem cell transplantation (HSCT) (8.94 x 106/kg CD34+ mononuclear 
cells) under a conditioning regimen of high-dose melphalan (200 mg/m2). 
There were no important complications in the post-transplantation period 
and no transfusion was necessary. Neutrophil recovery was observed 
on day +10. However, because of disease progression, thalidomide 
(200-400 mg/day) was started in June 2003. In June 2004, the patient 
underwent a non-myeloablative allogeneic stem cell transplantation 
(NST) from an HLA-identical sibling donor and mismatched ABO group 
(patient O+ and donor B+). Pretransplant serology for toxoplasmosis 
and cytomegalovirus (CMV) was IgM-negative and IgG-positive. The 
conditioning regimen included total body irradiation (200 cGy) and 
fludarabine (90 mg/m2). Graft-versus-host disease (GVHD) prophylaxis 
with cyclosporine-A and a short course of mycophenolate were initiated. 
The patient received 8.32 × 108 mononuclear cells/kg and 3.29 × 106 
CD34+ cells/kg. Neutrophil recovery was observed on day +5. Complete 
chimerism was documented by VNTR on days +28, +56, +122, +211 
and +909 after NST. The immunosupressor therapy was continued until 
day +56, when the GVHD prophylaxis was tapered off. 
In July 2005 (390 days post-NST), the patient presented fever, 
myalgia and headache. Serology for syphilis, hepatitis A, B and C 
and HIV was negative. The serology for CMV was IgM-negative and 
IgG-positive, whereas the serology for toxoplasmosis was positive for 
IgM, IgG and IgA antibodies. The donor’s serology for toxoplasmosis was 
negative for IgM and IgG antibodies. The patient was promptly treated 
with pyrimethamine, sulfadiazine, and folinic acid, and no complications 
related to toxoplasmosis have been observed up to now. 
The antibody concentrations for several infectious agents, including 
T. gondii, were measured in recipient serum samples at periodic intervals 
during follow-up (Table 1). Toxoplasma-specific IgM and IgG antibodies 
were determined by indirect immunofluorescence (IIF) and enzyme-
linked fluorescent assay (ELFA), using the VIDAS® system (BioMérieux, 
France). Toxoplasma-specific IgG avidity was also determined by ELFA 
using the VIDAS system. Anti-T. gondii IgA was measured by enzyme-
linked immunosorbent assay (ELISA) using PlateliaTM Toxo IgA kits 
(Bio-Rad, France). IIF was done as previously described9, and titers ≥ 32 
were considered positive. ELFA and ELISA were performed according 
to the manufacturers’ instructions. For the VIDAS system, IgM indices 
≥ 0.65 and antitoxoplasma IgG titers ≥ 8 international units per milliliter 
(IU/mL) were considered positive. The IgG avidity test allows specimens 
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to be classified as low (index < 0.2), borderline (0.2 < index < 0.3) or high 
(≥ 0.3) avidity. An avidity index ≥ 0.3 is a strong indication of a primary 
infection dating back more than four months. An index < 0.3 does not 
allow a recent infection to be differentiated from an old infection. In 
the ELISA for IgA, serum samples with a sample ratio (sample optical 
density/optical density for cut-off control serum) ≥ 1 were considered 
positive.
DISCUSSION
Toxoplasmosis is a rare but serious complication in allogeneic 
HSCT recipients3,5,7,8,10. Most cases of Toxoplasma infections occur in 
seropositive HSCT recipients, suggesting that toxoplasmosis usually 
results from the reactivation of latent tissue parasites5,8. In the present 
case, the seropositive recipient received hematopoietic stem cells from a 
seronegative donor. The primary response to T. gondii was supported by 
IgM and IgG seroconversion as shown by IIF, and IgA seroconversion 
as shown by ELISA. The IgG avidity test also detected low-avidity 
antibodies in the patient after infection with T. gondii; the low-avidity 
indices persisted for more than 14 months after the primary infection.
Most cases of toxoplasmosis after HSCT are only diagnosed at 
autopsy because histological evidence of organ involvement is rarely 
obtained before death6. The early detection of T. gondii DNA in body 
fluids by PCR methods has been considered an important tool for 
monitoring Toxoplasma infection following HSCT5,6. A recent study has 
shown the importance of monitoring toxoplasmosis after HSCT with 
biological tests that combine PCR and serological techniques3. This case 
stresses the importance of detecting anti-T. gondii antibodies in donors 
and recipients before transplantation, and of serologically monitoring 
the recipient during long-term follow-up.
RESUMO
Monitoramento sorológico de uma infecção toxoplásmica após 
transplante de células progenitoras hematopoiéticas
Esse relato de caso descreve uma resposta primária ao Toxoplasma 
gondii após transplante de células progenitoras hematopoiéticas em 
paciente com mieloma múltiplo. A resposta primária para o T. gondii 
foi evidenciada pela soroconversão observada na resposta de anticorpos 
IgM, IgG e IgA. O paciente foi prontamente tratado e complicações 
relacionadas à toxoplasmose não foram observadas nos meses 
subseqüentes. 
Table 1
Serological monitoring of the Toxoplasma infection
       
Days after 
transplant
Chimerism IgM-IIF 
(titer)
IgG-IIF 
(titer)
IgM-ELFA
(index)
IgG-ELFA
(IU/mL)
IgG avidity
(index)
IgA-ELISA
(POS/NEG)
0 autologous hematopoietic stem cell transplantation
1211 NR 512 NR 216 0.55 NEG
0 non-myeloablative allogeneic stem cell transplantation
28 complete ND ND ND ND ND ND
41 NR 256 NR 244 0.63 NEG
56 complete ND ND ND ND ND ND
122 complete ND ND ND ND ND ND
156 NR 64 NR 46 0.58 NEG
211 complete ND ND ND ND ND ND
390 fever, myalgia and headache
398 NR NR 2.70 30 0.37 POS
531 256 8 192 4.67 5 734 0.09 ND
551 256 16 384 3.93 6 682 0.09 ND
607 256 131 072 2.82 8 487 0.11 POS
622 128 131 072 2.54 7 985 0.11 POS
775 32 16 384 1.01 2 212 0.14 NEG
909 complete NR 8 192 0.81 1 210 0.18 NEG
945 NR 8 192 0.67 1 078 0.19 ND
972 NR 4 096 NR 1 060 0.19 ND
1036 ND ND NR 1 052 0.29 NEG
1044 ND ND NR 1 041 0.30 ND
1063 ND ND NR 1 000 0.30 ND
2135 ND ND NR 451 0.32 ND
Significant antibody results: IgM-IIF ≥ 32; IgM-ELFA ≥ 0.65; IgG-ELFA ≥ 8 IU/mL; IgA-ELISA = POS (POS = positive; NEG = negative); an avidity index ≥ 0.3 is a 
strong indication of a primary infection dating back more than four months; an index < 0.3 does not allow a recent infection to be differentiated from an old infection. 
NR = non-reactive; ND = not determined.
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